Michael Campbell, PhD
Professor
Surgery
School of Medicine

Websites

Show all (1) Hide

• Profile at UCSF Cancer Center (cancer.ucsf.edu)

Publications (62)

Top publication keywords:
FluoroimmunoassayNeoplasms, Second PrimaryMammary Neoplasms, ExperimentalImmunoglobulin IdiotypesBreast NeoplasmsDrugs, Chinese HerbalTumor MicroenvironmentAdrenal Gland NeoplasmsBiomarkers, TumorProliferating Cell Nuclear AntigenMacrophagesNeoadjuvant TherapyCarcinoma, Intraductal, NoninfiltratingPhytotherapyPlants, Medicinal

• Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
  JCO precision oncology 2025 Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, …
• Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
  JAMA oncology 2025 Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ
• Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
  Breast cancer research and treatment 2024 Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM…
• Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
  Cell reports. Medicine 2024 Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC,…
• Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
  mSystems 2024 McCune E, Sharma A, Johnson B, O'Meara T, Theiner S, Campos M, Heditsian D, Brain S, Gilbert JA, Esserman L, Campbell MJ

Show all (57 more) Hide

• Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
  NPJ breast cancer 2024 Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A
• Tumor microenvironmental determinants of high-risk DCIS progression.
  Research square 2024 Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L
• Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
  Cell reports. Medicine 2023 Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, …
• Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
  JAMA network open 2023 Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, …
• B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
  Breast cancer research : BCR 2023 Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, …
• Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards.
  Radiographics : a review publication of the Radiological Society of North America, Inc 2023 Chung R, Garratt J, Remer EM, Navin P, Blake MA, Taffel MT, Hackett CE, Sharbidre KG, Tu W, Low G, Bara M, Carney BW, Corwin MT, Campbell MJ, Lee JT, Lee CY, Dueber JC, Shehata MA, Caoili EM, Schieda …
• Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
  Cancer research communications 2022 Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ
• Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19.
  Surgery 2022 Collins RA, DiGennaro C, Beninato T, Gartland RM, Chaves N, Broekhuis JM, Reddy L, Lee J, Deimiller A, Alterio MM, Campbell MJ, Lee YJ, Khilnani TK, Stewart LA, O'Brien MA, Alvarado MVY, Zheng F, …
• Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
  NPJ breast cancer 2021 Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ
• Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
  Journal of mammary gland biology and neoplasia 2021 Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ
• Germline genetic contribution to the immune landscape of cancer.
  Immunity 2021 Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, …
• Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease?
  World journal of surgery 2020 Yanagisawa M, Malik DG, Loehfelm TW, Fananapazir G, Corwin MT, Campbell MJ
• Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
  Breast cancer research and treatment 2016 Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C
• Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
  Breast cancer research and treatment 2016 Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L
• The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
  PloS one 2013 Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ
• Biology of breast cancer in Nigerian women: a pilot study.
  Annals of African medicine 2012 Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ
• Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
  Annals of surgical oncology 2012 Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ
• Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
  Breast cancer research and treatment 2011 Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ
• Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
  Expert review of molecular diagnostics 2011 Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ
• Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
  Breast cancer research and treatment 2010 Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ
• Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
  Breast cancer research and treatment 2010 Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ
• Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
  Journal of cellular biochemistry 2008 Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID
• Breast cancer growth prevention by statins.
  Cancer research 2006 Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC
• Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
  Cancer gene therapy 2006 Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM
• A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Kumar AS, Campbell M, Benz CC, Esserman LJ
• Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
  Molecular cancer therapeutics 2006 Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF
• Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
  Breast cancer research and treatment 2005 Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID
• In vitro anticancer activity of twelve Chinese medicinal herbs.
  Phytotherapy research : PTR 2005 Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ
• Immune dysfunction and micrometastases in women with breast cancer.
  Breast cancer research and treatment 2005 Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ
• Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells.
  Cancer research 2004 Kim SW, Chao TH, Xiang R, Lo JF, Campbell MJ, Fearns C, Lee JD
• Reduction of MTT by aqueous herbal extracts in the absence of cells.
  Journal of ethnopharmacology 2004 Shoemaker M, Cohen I, Campbell M
• Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.
  Anticancer research 2002 Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D
• Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
  In vitro cellular & developmental biology. Animal 2002 Campbell MJ, Wollish WS, Lobo M, Esserman LJ
• Ductal growth is impeded in mammary glands of C-neu transgenic mice.
  Oncogene 2000 Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G
• Biological therapies for breast carcinoma: concepts for improvement in survival.
  Seminars in oncology 1999 Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM
• Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
  Cancer immunology, immunotherapy : CII 1999 Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ
• Clinical trials of idiotype-specific vaccine in B-cell lymphomas.
  Annals of the New York Academy of Sciences 1993 Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R
• Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
  The New England journal of medicine 1992 Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R
• Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction.
  Cancer research 1992 Kwak LW, Campbell MJ, Levy R
• Interleukin 3 is a growth factor for human follicular B cell lymphoma.
  The Journal of experimental medicine 1992 Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R, Krensky AM
• Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.
  Molecular immunology 1992 Campbell MJ, Zelenetz AD, Levy S, Levy R
• Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy.
  Blood 1991 Kwak LW, Campbell MJ, Zelenetz AD, Levy R
• Ig VH gene expression among human follicular lymphomas.
  Blood 1991 Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R
• Follicular lymphoma: a model of lymphoid tumor progression in man.
  Annals of oncology : official journal of the European Society for Medical Oncology 1991 Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S
• Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
  Cancer detection and prevention 1991 Kwak LW, Campbell M, Levy R
• Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
  Blood 1990 Kwak LW, Campbell MJ, Zelenetz AD, Levy R
• Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
  Journal of immunology (Baltimore, Md. : 1950) 1990 Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R
• Idiotypic variation in a human B lymphoma cell line.
  Journal of immunology (Baltimore, Md. : 1950) 1990 Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S, Levy R
• Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line.
  The Journal of experimental medicine 1989 Levy S, Campbell MJ, Levy R
• Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
  International reviews of immunology 1989 Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R
• Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Campbell MJ, Esserman L, Levy R
• Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC
• Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.
  Journal of immunology (Baltimore, Md. : 1950) 1988 Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R
• Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
  Journal of immunology (Baltimore, Md. : 1950) 1987 Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R
• Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses.
  Blood 1987 Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R
• Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies.
  Journal of immunology (Baltimore, Md. : 1950) 1986 Campbell M, Bieber M, Levy R, Teng NN
• Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
  Journal of immunology (Baltimore, Md. : 1950) 1986 Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R